IO Biotech stock plummets after FDA recommends against BLA submission
NegativeFinancial Markets

IO Biotech's stock has taken a significant hit following the FDA's recommendation against the submission of its Biologics License Application (BLA). This decision is crucial as it directly impacts the company's ability to bring its products to market, potentially delaying advancements in cancer treatment. Investors are understandably concerned about the future of IO Biotech, as regulatory hurdles can severely affect a biotech firm's prospects.
— Curated by the World Pulse Now AI Editorial System